Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
α-Glucosidase (AGS) is a therapeutic target for Type 2 diabetes mellitus (T2DM) that tends to complicate with other diseases. Some medications for the treatment of T2DM complications have the risk of inducing severe adverse reactions such as diarrhea via the metabolism of intestinal bacterial β-glucuronidase (BGUS). The development of new AGS and/or BGUS inhibitors may improve the therapeutic effects of T2DM and its complications. The present work focused on the isolation and characterization of AGS and/or BGUS inhibitors from the medicinal plant . A total of eight compounds were isolated and identified. Sphaerandralide A () was obtained as a previously undescribed triterpenoid, which may have chemotaxonomy significance in the authentication of the genus and . 2'-acetyl-4',4-dimethoxybiphenyl-2-carbaldehyde () was obtained from a plant source for the first time, while compounds - were isolated from for the first time. In the in vitro assay, compounds - showed potent to moderate activity against AGS. Interestingly, compound also exhibited significant BGUS inhibitory activity, demonstrating the potential of being developed as a bifunctional inhibitor that may find application in the therapy of T2DM and/or the diarrhea induced by medications for the treatment of T2DM complications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954508 | PMC |
| http://dx.doi.org/10.3390/ph15030329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health-Related Quality of Life and Psychosocial Outcomes in Patients With Type 2 Diabetes Mellitus: A Bibliometric Analysis.
J Diabetes Res
September 2025
Department of Immunochemistry, Institution of Chemical Engineering, Ural Federal University, Yekaterinburg, Russia.
Health-related quality of life (HRQoL) has become a critical focus in managing Type 2 diabetes mellitus (T2DM), emphasizing the need to integrate physiological, psychological, and social dimensions into clinical practice. Despite the growing prevalence of T2DM worldwide, particularly in low- and middle-income countries, the global research landscape of HRQoL remains unevenly distributed. This study is aimed at systematically analyzing the global research trends, key contributors, and influencing factors of HRQoL in patients with T2DM using bibliometric methods, providing insights to guide future research and targeted interventions.
View Article and Find Full Text PDFA machine learning model for predicting obesity risk in patients with diabetes mellitus: analysis of NHANES 2007-2018.
Front Public Health
September 2025
Department of Plastic and Reconstructive Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region & Research Center of Medical Sciences, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China.
Background: Obesity is a prevalent and clinically significant complication among individuals with diabetes mellitus (DM), contributing to increased cardiovascular risk, metabolic burden, and reduced quality of life. Despite its high prevalence, the risk factors for obesity within this population remain incompletely understood. With the growing availability of large-scale health datasets and advancements in machine learning, there is an opportunity to improve risk stratification.
View Article and Find Full Text PDFInhibition of CYP450 family 1 subfamily B member 1 (CYP1B1) expression in macrophage reduces the inflammatory response in type 2 diabetes mellitus combined with tuberculosis.
Front Endocrinol (Lausanne)
September 2025
School of Public Health, Inner Mongolia Medical University, Huhhot, China.
Type 2 diabetes (T2DM) and tuberculosis (TB) both regulate inflammation and may exert synergistic or antagonistic effects through shared immune pathways. Previous studies have demonstrated that T2DM is a risk factor for TB. However, at the level of gene regulatory networks, it remains unclear whether there are key interaction nodes linking these two diseases.
View Article and Find Full Text PDFLong-term impact of growth hormone therapy on mortality and type 2 diabetes in Prader-Willi syndrome: a nationwide cohort study.
Front Endocrinol (Lausanne)
September 2025
Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Background: Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by severe multisystem comorbidities and increased mortality. Although growth hormone therapy (GHT) is widely used as standard care, population-based evidence on its long-term safety, particularly in relation to mortality and type 2 diabetes mellitus (T2DM), remains limited. We aimed to investigate the associations between GHT duration, mortality, and T2DM incidence in PWS.
View Article and Find Full Text PDFA possible role for food-based citrus bioactive compounds in bridging the gap between prevalence of diabetes and the effectiveness of current treatments.
J Food Sci Technol
October 2025
KGK Science Inc., London, ON Canada.
The conventional "one-size-fits-all" approach to treating and managing type 2 diabetes mellitus (T2DM) has proven challenging. T2DM is a complex, heterogeneous disease and frequently coexists with other conditions like hypertension, obesity, and dyslipidemia, further complicating treatment decisions and outcomes. While advances in diabetes medications have been made, traditional treatment algorithms often focus on broad glycemic targets, neglecting the diverse needs of patients with different risk profiles associated with ethnicity, comorbidities, and preferences.
View Article and Find Full Text PDF